Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia

American Journal of Hematology

Volumn 83, Issue 3, 2008, Pages 212-217

  Chan, Maren ^a   Malynn, Elizabeth ^a   Shaz, Beth ^b   Uhl, Lynne ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; THROMBOSIS;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION TESTS; CORONARY ARTERY BYPASS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 39749201660     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21074     Document Type: Article

References (27)

1. Warkentin TE. Heparin-induced thrombocytopenia, Part 1: The diagnostic clues. J Crit Illn 2002;17:172-178.
2. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005;127:35S-45S.
3. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-1292.
4. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
5. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia. A critical review. Arch Intern Med 2004;164:361-369.
6. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007;35:1165-1176.
7. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-851.
8. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003;108:2062-2065.
9. Warkentin TE, Sheppard JA, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need? J Lab Clin Med 2005;146:341-346.
10. Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-1708.
11. Zwicker JI, Uhl L, Huang WY, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004;2:2133-2137.
12. Warkentin TE, Greinacher A. Heparin-induced Thrombocytopenia, 3rd ed. New York: P. Marcel Dekker; 2004.
13. Arepally G, Reynolds C, Tomaski A, et al. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995;104:648-654.
14. Francis JL. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex. Semin Thromb Hemost 2004;30:359-368.
15. Eichler P, Raschke R, Lubenow N, et al. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 2002;116:887-891.
16. Refaai MA, Laposata M, Van Cott EM. Clinical significance of a borderline titer in a negative ELISA test for heparin-induced thrombocytopenia. Am J Clin Pathol 2003;119:61-65.
17. Warkentin TE. Heparin-induced thrombocytopenia: Diagnosis and management. Circulation 2004;110:e454-e458.
18. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-765.
19. Warkentin T. Clinical and laboratory diagnosis of HIT. In: Chong B, editor. Refining the Scoring System. ISTH SSC Subcommittee on Platelet Immunology; 2002. http://www.med.unc.edu/isth/ssc/02sscminutes/02plateletimmun. html
20. Aster RH. Heparin-induced immune thrombocytopenia - A clinical or laboratory diagnosis? J Thromb Haemost 2006;4:757-758.
21. GTI Diagnostics, PF4 Enhanced, Package Insert, Waukesha, WI, January 2005.
22. Suh JS, Malik MI, Aster RH, et al. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol 1997;54:196-201.
23. Amiral J, Pouplard C, Vissac AM, et al. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: Biological characteristics and effects on platelet activation. Br J Haematol 2000;109:336-341.
24. Ahmad S, Untch B, Haas S, et al. Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: Implications in the HIT pathogenesis. Mol Cell Biochem 2004;258:163-170.
25. Eslin DE, Zhang C, Samuels KJ, et al. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: Dissociation between anticoagulant and antithrombotic effect of heparin. Blood 2004;104:3173-3180.
26. Rauova L, Zhai L, Kowalska MA, et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: Diagnostic and therapeutic implications. Blood 2006;107:2346-2353.
27. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006;355:809-817.